{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:53:33Z","timestamp":1793116413209,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82271667"],"award-info":[{"award-number":["No. 82271667"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Outstanding Scientific Fund of Shengjing Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-02082-0","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T12:15:19Z","timestamp":1764677719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effects of chiglitazar and metformin on insulin resistance in women with a normal BMI and polycystic ovary syndrome: a randomized controlled study"],"prefix":"10.1186","volume":"25","author":[{"given":"Yining","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"2082_CR1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/humrep\/dep399","volume":"25","author":"WA March","year":"2010","unstructured":"March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25:544\u201351. https:\/\/doi.org\/10.1093\/humrep\/dep399.","journal-title":"Hum Reprod"},{"key":"2082_CR2","unstructured":"Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice [Internet]. PubMed. [cited 2024 Sept 10]. https:\/\/pubmed.ncbi.nlm.nih.gov\/26602525\/."},{"key":"2082_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/humrep\/des463","volume":"28","author":"NK Stepto","year":"2013","unstructured":"Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28:777\u201384. https:\/\/doi.org\/10.1093\/humrep\/des463.","journal-title":"Hum Reprod"},{"key":"2082_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","volume":"37","author":"RL Rosenfield","year":"2016","unstructured":"Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37:467\u2013520. https:\/\/doi.org\/10.1210\/er.2015-1104.","journal-title":"Endocr Rev"},{"key":"2082_CR5","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.2147\/DMSO.S329108","volume":"14","author":"W Shi","year":"2021","unstructured":"Shi W, Zhao Q, Zhao X, Xing C, He B. Analysis of endocrine and metabolic indexes in Non-Obese patients with polycystic ovary syndrome and its compare with obese patients. Diabetes Metab Syndr Obes. 2021;14:4275\u201381. https:\/\/doi.org\/10.2147\/DMSO.S329108.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2082_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5455\/medarh.2020.74.289-293","volume":"74","author":"Z Saadia","year":"2020","unstructured":"Saadia Z. Follicle stimulating hormone (LH: FSH) ratio in polycystic ovary syndrome (PCOS) - obese vs. Non- obese women. Med Arch. 2020;74:289\u201393. https:\/\/doi.org\/10.5455\/medarh.2020.74.289-293.","journal-title":"Med Arch"},{"key":"2082_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/s0889-8529(05)70286-3","volume":"26","author":"VT Goudas","year":"1997","unstructured":"Goudas VT, Dumesic DA. Polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1997;26:893\u2013912. https:\/\/doi.org\/10.1016\/s0889-8529(05)70286-3.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2082_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.beem.2006.03.008","volume":"20","author":"KM Hoeger","year":"2006","unstructured":"Hoeger KM. Role of lifestyle modification in the management of polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2006;20:293\u2013310. https:\/\/doi.org\/10.1016\/j.beem.2006.03.008.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2082_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ncpendmet0787","volume":"4","author":"A Dunaif","year":"2008","unstructured":"Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome\u2013a reappraisal. Nat Clin Pract Endocrinol Metab. 2008;4:272\u201383. https:\/\/doi.org\/10.1038\/ncpendmet0787.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2082_CR10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.fertnstert.2021.04.018","volume":"116","author":"S Persson","year":"2021","unstructured":"Persson S, Elenis E, Turkmen S, Kramer MS, Yong E-L, Poromaa IS. Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome. Fertil Steril. 2021;116:862\u201371. https:\/\/doi.org\/10.1016\/j.fertnstert.2021.04.018.","journal-title":"Fertil Steril"},{"key":"2082_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.0.1380269","volume":"138","author":"E Diamanti-Kandarakis","year":"1998","unstructured":"Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998;138:269\u201374. https:\/\/doi.org\/10.1530\/eje.0.1380269.","journal-title":"Eur J Endocrinol"},{"key":"2082_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0168-3659(00)00374-6","volume":"71","author":"D Stepensky","year":"2001","unstructured":"Stepensky D, Friedman M, Srour W, Raz I, Hoffman A. Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR Metformin formulation. J Control Release. 2001;71:107\u201315. https:\/\/doi.org\/10.1016\/s0168-3659(00)00374-6.","journal-title":"J Control Release"},{"key":"2082_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13048-024-01367-7","volume":"17","author":"H Zhao","year":"2024","unstructured":"Zhao H, Zhang J, Xing C, Cheng X, He B. Metformin versus Metformin plus Pioglitazone on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial. J Ovarian Res. 2024;17:42. https:\/\/doi.org\/10.1186\/s13048-024-01367-7.","journal-title":"J Ovarian Res"},{"key":"2082_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","volume":"20","author":"RE Soccio","year":"2014","unstructured":"Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20:573\u201391. https:\/\/doi.org\/10.1016\/j.cmet.2014.08.005.","journal-title":"Cell Metab"},{"key":"2082_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","volume":"106","author":"D Lizneva","year":"2016","unstructured":"Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6\u201315. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.05.003.","journal-title":"Fertil Steril"},{"key":"2082_CR16","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3305\/nh.2013.28.5.6512","volume":"28","author":"S Henr\u00edquez","year":"2013","unstructured":"Henr\u00edquez S, Jara N, Bunout D, Hirsch S, de la Maza MP, Leiva L, et al. Variability of formulas to assess insulin sensitivity and their association with the Matsuda index. Nutr Hosp. 2013;28:1594\u20138. https:\/\/doi.org\/10.3305\/nh.2013.28.5.6512.","journal-title":"Nutr Hosp"},{"key":"2082_CR17","unstructured":"Profound peripheral insulin. resistance, independent of obesity, in polycystic ovary syndrome [Internet]. PubMed. [cited 2025 Mar 4]. https:\/\/pubmed.ncbi.nlm.nih.gov\/2670645\/."},{"key":"2082_CR18","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.2337\/diacare.26.12.3320","volume":"26","author":"JF Ascaso","year":"2003","unstructured":"Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26:3320\u20135. https:\/\/doi.org\/10.2337\/diacare.26.12.3320.","journal-title":"Diabetes Care"},{"key":"2082_CR19","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.25122\/jml-2023-0040","volume":"16","author":"SRM Hussein","year":"2023","unstructured":"Hussein SRM, Sadiq AM, Johar SA, Nasrawi AJM. Insulin level, lipid profile, and HOMA index in lean and obese patients with polycystic ovary syndrome. J Med Life. 2023;16:1258. https:\/\/doi.org\/10.25122\/jml-2023-0040.","journal-title":"J Med Life"},{"key":"2082_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.fertnstert.2004.02.127","volume":"82","author":"J-P Baillargeon","year":"2004","unstructured":"Baillargeon J-P, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of Metformin and rosiglitazone, alone and in combination, in Nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82:893\u2013902. https:\/\/doi.org\/10.1016\/j.fertnstert.2004.02.127.","journal-title":"Fertil Steril"},{"key":"2082_CR21","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.scib.2021.03.019","volume":"66","author":"L Ji","year":"2021","unstructured":"Ji L, Song W, Fang H, Li W, Geng J, Wang Y, et al. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). Sci Bull (Beijing). 2021;66:1571\u201380. https:\/\/doi.org\/10.1016\/j.scib.2021.03.019.","journal-title":"Sci Bull (Beijing)"},{"key":"2082_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1210\/jcem-66-1-165","volume":"66","author":"J Waldstreicher","year":"1988","unstructured":"Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab. 1988;66:165\u201372. https:\/\/doi.org\/10.1210\/jcem-66-1-165.","journal-title":"J Clin Endocrinol Metab"},{"key":"2082_CR23","unstructured":"Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome [Internet]. PubMed. [cited 2024 Oct 21]. https:\/\/pubmed.ncbi.nlm.nih.gov\/9215302\/."},{"key":"2082_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.fertnstert.2003.05.020","volume":"81","author":"AD Genazzani","year":"2004","unstructured":"Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in Nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004;81:114\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2003.05.020.","journal-title":"Fertil Steril"},{"key":"2082_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/s-2007-1016208","volume":"17","author":"L Tseng","year":"1999","unstructured":"Tseng L, Mazella J. Prolactin and its receptor in human endometrium. Semin Reprod Endocrinol. 1999;17:23\u20137. https:\/\/doi.org\/10.1055\/s-2007-1016208.","journal-title":"Semin Reprod Endocrinol"},{"key":"2082_CR26","doi-asserted-by":"publisher","first-page":"571229","DOI":"10.3389\/fendo.2021.571229","volume":"12","author":"H Yang","year":"2021","unstructured":"Yang H, Lin J, Li H, Liu Z, Chen X, Chen Q. Prolactin is associated with insulin resistance and Beta-Cell dysfunction in infertile women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2021;12:571229. https:\/\/doi.org\/10.3389\/fendo.2021.571229.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2082_CR27","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/humrep\/deu133","volume":"29","author":"D Glintborg","year":"2014","unstructured":"Glintborg D, Altinok M, Mumm H, Buch K, Ravn P, Andersen M. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. Hum Reprod. 2014;29:1773\u20139. https:\/\/doi.org\/10.1093\/humrep\/deu133.","journal-title":"Hum Reprod"},{"key":"2082_CR28","unstructured":"Evaluation of endocrine. changes in women with the polycystic ovary syndrome during metformin treatment [Internet]. PubMed. [cited 2024 Oct 26]. https:\/\/pubmed.ncbi.nlm.nih.gov\/23988170\/."},{"key":"2082_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/09513590902770172","volume":"25","author":"E Billa","year":"2009","unstructured":"Billa E, Kapolla N, Nicopoulou SC, Koukkou E, Venaki E, Milingos S, et al. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2009;25:427\u201334. https:\/\/doi.org\/10.1080\/09513590902770172.","journal-title":"Gynecol Endocrinol"},{"key":"2082_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/BF03345321","volume":"28","author":"F Bogazzi","year":"2005","unstructured":"Bogazzi F, Russo D, Locci MT, Chifenti B, Ultimieri F, Raggi F, et al. Peroxisome proliferator-activated receptor (PPAR)gamma is highly expressed in normal human pituitary gland. J Endocrinol Invest. 2005;28:899\u2013904. https:\/\/doi.org\/10.1007\/BF03345321.","journal-title":"J Endocrinol Invest"},{"key":"2082_CR31","unstructured":"Oocyte Competence in Women with Polycystic Ovary Syndrome [Internet]. PubMed. [cited 2024 Oct 31]. https:\/\/pubmed.ncbi.nlm.nih.gov\/27988256\/."},{"key":"2082_CR32","doi-asserted-by":"publisher","first-page":"111141","DOI":"10.1016\/j.intimp.2023.111141","volume":"125","author":"Y Xiang","year":"2023","unstructured":"Xiang Y, Wang H, Ding H, Xu T, Liu X, Huang Z, et al. Hyperandrogenism drives ovarian inflammation and pyroptosis: A possible pathogenesis of PCOS follicular dysplasia. Int Immunopharmacol. 2023;125:111141. https:\/\/doi.org\/10.1016\/j.intimp.2023.111141.","journal-title":"Int Immunopharmacol"},{"key":"2082_CR33","doi-asserted-by":"publisher","first-page":"105829","DOI":"10.1016\/j.jsbmb.2021.105829","volume":"208","author":"P Cui","year":"2021","unstructured":"Cui P, Hu W, Ma T, Hu M, Tong X, Zhang F, et al. Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats. J Steroid Biochem Mol Biol. 2021;208:105829. https:\/\/doi.org\/10.1016\/j.jsbmb.2021.105829.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2082_CR34","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1007\/s43032-022-00985-0","volume":"29","author":"J Ge","year":"2022","unstructured":"Ge J, Yang N, Zhang X, Li M, Zhang W, He J, et al. Steroid hormone profiling in hyperandrogenism and Non-hyperandrogenism women with polycystic ovary syndrome. Reprod Sci. 2022;29:3449\u201358. https:\/\/doi.org\/10.1007\/s43032-022-00985-0.","journal-title":"Reprod Sci"},{"key":"2082_CR35","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/s0015-0282(00)00501-x","volume":"73","author":"B Kolodziejczyk","year":"2000","unstructured":"Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril. 2000;73:1149\u201354. https:\/\/doi.org\/10.1016\/s0015-0282(00)00501-x.","journal-title":"Fertil Steril"},{"key":"2082_CR36","doi-asserted-by":"publisher","unstructured":"Zhang J, Xing C, Cheng X, He B. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial. Front Endocrinol (Lausanne) [Internet]. 2022 [cited 2025 Sept 27];13. https:\/\/doi.org\/10.3389\/fendo.2022.1003238.","DOI":"10.3389\/fendo.2022.1003238"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02082-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-02082-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02082-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:34:35Z","timestamp":1766993675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-025-02082-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2082"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-02082-0","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single-center, open-label, 1:1 randomized controlled trial received approval from the Scientific Research and New Technology Ethical Committee of Shengjing Hospital of China Medical University (No. 2023PS581K) and was registered with ClinicalTrials (NCT06125587) on 2023-11-05 in accordance with the Declaration of Helsinki. Prior to their participation, all patients were informed about the study\u2019s objectives and provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"283"}}